Biosimilar Monoclonal Antibodies Market Size, Share, Trend, Scope Report 2026 to 2035
What is Biosimilar Monoclonal Antibodies Market Size?
Global Biosimilar Monoclonal Antibodies Market Size is valued at USD 8.84 Billion in 2025 and is predicted to reach USD 36.94 Billion by the year 2035 at a 15.5% CAGR during the forecast period for 2026 to 2035.
Biosimilar Monoclonal Antibodies Market Size, Share & Trends Analysis Report By Product (Infliximab, Trastuzumab, Rituximab, Adalimumab, Bevacizumab, Cetuximab, Ranibizumab, Denosumab, Eculizumab, Other Pipeline Products), By Indication, By Region, And Segment Forecasts, 2026 to 2035.
Biosimilar Monoclonal Antibodies Market Key Takeaways:
|
Key Industry Insights & Findings from the Report:
- The rising occurence of chronic diseases like cancer, autoimmune disorders, and inflammatory diseases is driving the biosimilar monoclonal antibodies market.
- The termination of patents plays a pivotal role in propelling the growth of the biosimilar monoclonal antibody market.
- North America dominated the market and accounted for a global revenue share in 2024.
- The key challenge for the Biosimilar Monoclonal Antibodies Market is the high cost of development processes and complex manufacturing procedures.
Biosimilars are biological drugs, and they are large, complex biological molecules produced from living organisms that are often difficult to characterize and therefore difficult to copy. Monoclonal antibody biosimilars play a vital role in treating various chronic and autoimmune diseases. They also represent an opportunity to increase access and reduce costs for patients and healthcare systems.
Global Biosimilar Monoclonal Antibodies market growth is attributed to numerous factors such as biosimilar monoclonal antibodies market include the increasing patent expiries of mAbs, innovation of advanced mAbs, the growing number of biosimilars for oncology treatments, rising demand for lower-priced, cost-efficient biosimilar monoclonal antibodies, growing chronic and autoimmune diseases like cancer, rheumatoid arthritis, diabetes, and the rising older population. Moreover, increasing R&D investments for biological drugs are anticipated to fuel market adoption during the forecast period. Growing R&D activities result in innovative drug products, developmental procedures, and healthcare facilities, thereby boosting market growth.
However, the high cost of development processes, complex mAb manufacturing procedures, region-specific government rules regarding the production and use of biosimilars, lack of scientific standards for biosimilars are expected to hamper the market's growth in the coming years.
Competitive Landscape
Some Of The Key Players In The Biosimilar Monoclonal Antibodies Market:
- Accord BioPharma Inc.
- Alvotech USA Inc.
- Amgen Inc.
- Amneal Pharmaceuticals LLC
- Biocon Biologics Inc.
- Biogen Netherlands B.V.
- Biosimilar Collaborations Ireland Limited
- Bio-Thera Solutions, Ltd.
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Celltrion Healthcare Hungary Kft.
- Coherus BioSciences, Inc.
- CuraTeQ Biologics s.r.o
- Eli Lilly and Company
- FGK Representative Service GmbH
- Formycon AG
- Fresenius Kabi
- Gedeon Richter Plc.
- Hexal AG
- Hong Kong King-Friend Industrial Company Limited
- Hospira Inc., a Pfizer Company
- Juta Pharma GmbH
- Kashiv BioSciences, LLC
- Mabxience Research SL
- Medice Arzneimittel Pütter GmbH KG
- Midas Pharma GmbH
- Mundipharma Corporation (Ireland) Limited
- Pfizer Inc.
- Qilu Pharma Spain S.L.
- Ratiopharm GmbH
- Reddy Holding GmbH
- Samsung Bioepis Co., Ltd.
- Sandoz Inc.
- Sanofi
- Stada Arzneimittel AG
- Strides Pharma (Cyprus) Limited
- Tanvex BioPharma USA, Inc.
- Techdow Pharma Netherlands B.V.
- Teva GmbH
- Theramex Ireland Limited
- Other prominent players
Market Segmentation
The Biosimilar Monoclonal Antibodies Market is segmented based on product, indication, and region. By product, the market comprises the infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products. The infliximab and rituximab segments are projected to hold the highest market share over the forecast period owing to their increasing use in treating various chronic and autoimmune diseases. The market is classified into oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications based on the indication. Among all, The oncology segment is predictable to dominate the market in the coming years due to the surge in biosimilar mAbs approvals for cancer treatments. Regionally, the market is categorized across North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
North America region dominated this market in 2020 and is expected to continue its trend over the forecast period on account of the favourable reimbursement policies, increasing patent expiration, and the growing rate of biosimilar mAbs approvals.
Recent Developments:
- In May 2024, Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has received FDA approval for Yesafili™ (aflibercept-jbvf), its biosimilar of EYLEA® (aflibercept), which is the first of its kind to be filed and is interchangeable. Yesafili™ is used in the treatment of several ophthalmic diseases.
The Biosimilar Monoclonal Antibodies Market Report Scope
| Report Attribute | Specifications |
| Market Size Value In 2025 | USD 8.84 Billion |
| Revenue Forecast In 2035 | USD 36.94 Billion |
| Growth Rate CAGR | CAGR of 15.5% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Bn, and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Products, By Indication |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Pfizer, Novartis, Allergan, Coherus BioSciences, Biocon, Amgen, Boehringer Ingelheim, Celltrion, BioXpress Therapeutics, Intas Pharmaceuticals Limited, Genor BioPharma Co., Ltd, BIOCAD, Reddys Laboratories Ltd, 3SBio, Reliance Life Sciences, Hisun Pharma, Celgen Biopharma, Torrent Pharmaceuticals, Cadila Healthcare, Mylan Inc., BioXpress Therapeutics SA, Celltrion, EirGenix, Inc., Teva Pharmaceutical Industries Ltd., ALTEOGEN Inc., Apotex (Apobiologix), AryoGen Pharmed, Prestige BioPharma (PBP), PlantForm Outlook Therapeutics (Oncobiologics), Shanghai CP Guojian Pharmaceutical, Shanghai Henlius Biotech, Stada Arzneimittel AG, Other Prominent Players |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of Biosimilar Monoclonal Antibodies Market
Global Biosimilar Monoclonal Antibodies Market, by Product,
- Infliximab
- Trastuzumab
- Rituximab
- Adalimumab
- Bevacizumab
- Ranibizumab
- Denosumab
- Eculizumab
- Filgrastim
- Pegfilgrastim
- Ustekinumab
- Other Pipeline Products
Global Biosimilar Monoclonal Antibodies Market, by Indication, Autoimmune Diseases
- Oncology
- Ophthalmic Disorders
- Bone Disorders
- Rare Hematologic/Neurologic Disorders
- Hematologic Support
- Inflammatory Bowel Disease
- Other Indication
Global Biosimilar Monoclonal Antibodies Market, by Region,
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
North America
- U.S.
- Canada
Europe
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific Biosimilar
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East & Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Pfizer, Novartis, Allergan, Coherus BioSciences, Biocon, Amgen, Boehringer Ingelheim, Celltrion, BioXpress Therapeutics, Intas Pharmaceuticals Limited
Biosimilar Monoclonal Antibodies Market Size is valued at USD 8.84 Billion in 2025 and is predicted to reach USD 36.94 Billion by the year 2035.
Biosimilar Monoclonal Antibodies Market is expected to grow at a 15.5% CAGR during the forecast period for 2026-2035.
Biosimilar Monoclonal Antibodies Market is segmented based on product, indication, and region, infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products.
North America region is leading the Biosimilar Monoclonal Antibodies Market.